Background Anti-tumour necrosis factor-a drugs (antiTNFs) have revolutionised the treatment of rheumatoid arthritis (RA). More effective than standard non-biological disease-modifying anti-rheumatic drugs (nbDMARDs), antiTNFs are also substantially more expensive. Consequently, a number of model-based economic evaluations have been conducted to establish the relative cost-effectiveness of antiTNFs. However, anti-TNFs are associated with an increased risk of adverse drug events (ADEs) such as serious infections relative to nbDMARDs. Such ADEs will likely impact on both the costs and consequences of anti-TNFs, for example, through hospitalisations and forced withdrawal from treatment. Objective The aim of this review was to identify and critically appraise if, and how, ADEs have been incorporated into model-based cost-effectiveness analyses of antiTNFs for adult patients with RA. Methods A systematic literature review was performed. Electronic databases (Ovid MEDLINE; Ovid EMBASE; Web of Science; NHS Economic Evaluations Database) were searched for literature published between January 1990 and October 2013 using electronic search strategies. The reference lists of retrieved studies were also hand searched. In addition, the National Institute for Health and Care Excellence technology appraisals were searched to identify economic models used to inform UK healthcare decision making. Only full economic evaluations that had used an economic model to evaluate biological DMARDs (bDMARDs) (including anti-TNFs) for adult patients with RA and had incorporated the direct costs and/or consequences of ADEs were critically appraised. To be included, studies also had to be available as a full text in English. Data extracted included general study characteristics and information concerning the methods used to incorporate ADEs and any associated assumptions made. The extracted data were synthesised using a tabular and narrative format. Results A total of 43 model-based economic evaluations of bDMARDs for adult RA were identified from 2,483 initially identified studies (2,473 published; ten technology appraisals). Of these, nine studies had incorporated the incidence and costs of ADEs and were critically reviewed. One study also explicitly estimated the potential consequences for patient utility. There was a general lack of detail specifically reporting on how ADEs were included in the economic models. Furthermore, there was substantial heterogeneity amongst the nine studies concerning the (i) application of risk-related terminology; (ii) method of incorporating the incidence, costs and consequences of ADEs; and (iii) ADE-related assumptions. Conclusions Model-based economic evaluations have played an integral role in healthcare reimbursement and funding decisions relating to anti-TNFs for adult patients with RA. However, current economic models have not routinely or systematically considered the direct costs or consequences of ADEs, which may bias the estimates of the relative PharmacoEconomics (2014) 32:109-134 DOI 10.1007 cost-effectiveness of anti-TNFs. Omitting information on relevant costs and consequences of interventions for RA will affect the validity of the associated recommendations for informed decision making. To improve current practice it is recommended that (i) greater efforts be made to provide appropriate long-term safety data on the use of anti-TNFs in adult RA; (ii) empirical research be undertaken to identify and quantify the impact of, and possible methods for, including ADEs in economic models to inform future good practice guidelines; and (iii) economic modelling guidelines and reference cases be updated to explicitly identify ADEs as an important treatment outcome and address how they might be incorporated into economic models. Improved consideration of the possible implications of ADEs in economic models will ensure that healthcare decision makers are provided with reliable and accurate information with which to make efficient reimbursement and financing decisions.
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Introduction and Background
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease of unknown aetiology characterised by an inflammation of the synovial joint tissue. Approximately 0.8 % of the UK's adult population, and relatively more women than men, are affected [1] . The precise course of RA varies, but individuals typically experience irreversible erosion of joint tissue, increasing functional disability, and potentially arthroplasty. As a systemic disease, the pathogenesis of RA can also result in extra-articular manifestations culminating in widespread damage to arterial organs such as the heart and lungs. Consequently people with RA face higher than average mortality and morbidity rates, and can expect a lower health-related quality of life (HRQoL) [2] .
Symptom onset peaks between 40 and 60 years of age [3] . With the capacity to work negatively related to disease progression [3] , RA-related early retirements result in significant economic costs [4, 5] ; productivity losses alone are estimated to cost the UK economy around £8 billion/ year [6] . Direct healthcare costs are also substantial [5, 7] . Traditionally driven by inpatient care relating to jointreplacement surgery [8] , the total direct cost of RA was estimated to exceed £600 million in 1992 by the most recent UK cost-of-illness study (in excess of £1 billion when inflated to 2011 prices) [9] .
The advent of pharmacological treatments that effectively retard disease progression, such as anti-tumour necrosis factor-a drugs (anti-TNFs), a class of biological disease-modifying anti-rheumatic drugs (bDMARDs), could therefore afford a substantial clinical and economic benefit [10] . Although not effective in all RA patients, antiTNFs offer the potential for greater symptom control and pain management than non-biological DMARDs (nbDMARDs), the current mainstay of RA standard care [11] , leading to gains in patient HRQoL. However, because of the immunosuppressive nature of anti-TNFs, concerns have been raised over their safety profile [11] [12] [13] [14] . Current evidence shows patients with RA treated with anti-TNFs do face a heightened risk of serious infections [15, 16] . Moreover, anti-TNFs have been associated with a statistically significant increased risk of serious infections compared with nbDMARDs [13, 17, 18] . Serious infections (see Dixon et al. [17] for a definition) occurring whilst on an anti-TNF are examples of adverse drug events (ADEs) [18] [19] [20] . Careful distinction between adverse events (see Craig et al. [21] for a definition) and ADEs (see the European Medicines Agency [22] for a definition) is especially pertinent for drug therapies for RA since the immunomodulatory action of the disease itself [17] , the presence of comorbidities, and early implementation of aggressive drug treatment strategies [23, 24] are known
Key Points for Decision Makers
• The implications of adverse drug events (ADEs) from anti-tumour necrosis factor-a drugs (anti-TNFs) for healthcare resources and patient health-related quality of life (HRQoL) have not been widely considered in existing model-based economic evaluations of biological disease-modifying anti-rheumatic drugs (bDMARDs) for adult patients with rheumatoid arthritis (RA).
• Omitting important, patient-relevant outcomes like
ADEs from anti-TNFs from economic models will likely bias the resulting cost-effectiveness estimates presented to healthcare decision makers.
• To prevent potential misinterpretation of the available evidence, it is recommended that economic models explicitly report the methods used to include ADEs and their potential impact on the costs and consequences of treatment.
• Future economic evaluations would benefit from using correct terminology to clearly distinguish key concepts such as ADEs from adverse events more generally, and by being aware of the implications of difference in terms for the selection,and availability, of data suitable for use in the economic models.
• To help healthcare decision makers make efficient financing and reimbursement decisions, an improved evidence base on the potential short-and long-term impacts of ADEs on healthcare resources and patient outcomes from longitudinal prospective studies and patient registries is required.
• Clearer guidance in current best practice guidelines for economic models on how the costs and consequences of ADEs should be included would assist analysts and improve the credibility and robustness of the associated estimates of the relative cost-effectiveness of health technologies.
aggravators of serious infections [25, 26] . Consequently, a 'serious infection' may be an ADE if the incident is considered attributable to a specific drug, but is an adverse event otherwise. 1 Incidents of severe ADEs cause significant harm to patients. The ADE will likely elicit a direct disutility, while the preclusion of continued treatment will result in an indirect disutility, since stopping treatment will see a worsening of the disease in the long run. ADEs may also result in a substantial use of healthcare resources, for example, from lengthy stays in hospital [18] .
The anti-TNFs are also considerably more expensive than nbDMARDs [27] . In a healthcare system faced with finite resources, evidence of gains in clinical effectiveness is a necessary but no longer sufficient requirement for the reimbursement or financing of new medicines [28] . Consequently, numerous economic evaluations of anti-TNFs for adult patients with RA have been published [29] to inform healthcare decision makers of the relative cost-effectiveness of these drugs. The use of decision analytic models (hereafter termed 'economic models') is now widely recommended to capture the multidimensional, heterogeneous and uncertain costs and consequences of alternative treatment options within economic evaluations of chronic diseases like RA [29, 30] .
To date, UK-relevant model-based economic evaluations have considered all five currently available anti-TNFs to be cost effective for use in late-stage RA [31, 32] . However, it is not clear to what extent the dis-benefits of anti-TNFs, specifically ADEs, have been taken into account in these existing evaluations. In particular, it is uncertain whether the negative impact on patient HRQoL and the additional demands on healthcare resources resulting from ADEs were considered. The aim of this study was to identify if, and how, current economic evaluations using decision analytic models to estimate the relative cost-effectiveness of anti-TNFs for adult RA have considered the impact of ADEs on the costs and consequences of treatment. A critical review of the economic models that have considered the costs and/or consequences of ADEs is presented, with a view to improving future economic models of drug treatments for RA.
Methods

Literature Search
The electronic databases Ovid MEDLINE (In-Process and Other Non-Indexed Citations' version), Ovid EMBASE, Web of Science, and NHS Economic Evaluations Database (accessed via the Centre for Reviews and Dissemination databases) were systematically searched (January 1990-October 2013) to identify model-based economic evaluations published in peer-reviewed journals. Electronic search strategies [33] were designed for each respective database, and combined index and free-text terms for RA, bDMARDs, and generic and brand names for currently available anti-TNFs, identified from keywords in relevant texts, with the Centre for Reviews and Disseminatio (CRD) economics filter [34] . Each search strategy was verified by a specialist librarian (personal communication Mary Ingram, The University of Manchester; July 2012) (see Online Resource 1 for search strategies employed).
The electronic searches were supplemented with a hand search of economic models used as part of the National Institute for Health and Care Excellence (NICE) technology appraisal (TA) process. All reports relevant to RA were obtained from the publicly available website (see http://www.nice.org.uk). Retrieved reports included economic models submitted by independent academic technology assessment groups (TAGs) and the manufacturers of the drug(s) being appraised. Where revisions to an original TA had been made, both the original and replacement reports were reviewed. Where the same economic model had been employed, the most recent version was considered for inclusion in the critical review. Summaries of manufacturers' models presented in the TAG reports for multiple TAs were not considered as separate studies.
In addition, the reference lists of relevant studies were hand searched to identify further studies meeting the inclusion criteria. All searches were performed in October 2013 (week 44).
Inclusion Criteria and Study Selection for Critical Review
Two reviewers independently screened all retrieved titles and abstracts to identify the studies eligible for inclusion in the critical review. One reviewer (EH) then screened the full-text versions of identified studies for eligibility. Studies were included if they met the inclusion criteria summarised in Table 1 . For the purposes of the screening process only, different risk-related terms (e.g. toxicity, adverse event, side effect) were considered synonymous with 'ADE.' Studies were therefore considered relevant if they had included the costs and/or consequences from any drug-related adverse outcome. All identified model-based economic evaluations of anti-TNFs were summarised, but only studies that considered the direct healthcare cost or impact on patient HRQoL of ADEs were critically appraised.
Data Collection and Extraction
Data were extracted from the identified studies by one reviewer (EH) using a structured data collection form that focussed on recording if, and how, ADEs had been included in the economic models. The de novo data extraction form was developed based on checklists designed by the School of Health and Related Research (ScHARR) TAG [35] and a recent health technology assessment report [21] . The data extracted encompassed (i) summary study characteristics (type of evaluation, population, interventions, data sources); (ii) general model assumptions (time horizon, health states, resource use, costs, HRQoL); and (iii) details specific to ADE parameters (incidence, resource use, costs, HRQoL). The studies were also assessed in terms of (i) the methods and assumptions employed to include an ADE in the economic model and (ii) the quality of the study reporting. Results were tabulated and then summarised in a narrative synthesis. Figure 1 summarises the study identification and inclusion process. The search of electronic databases identified 2,483 published studies, which were screened for eligibility. Hand searches revealed ten eligible NICE TAs and a further two published studies of relevance. A total of 72 studies were reviewed: 62 published studies and the ten NICE TAs. The ten TAs encompassed six economic models submitted by manufacturers (single TAs [36] [37] [38] [39] [40] [41] ), and four TAG assessment reports [32, [42] [43] [44] , which included eight critical reviews of manufacturers' models. The TAG assessment reports all used modified versions of the same economic model: the Birmingham Rheumatoid Arthritis Model (BRAM) [45] .
Results
Overview
Of the 72 studies reviewed, 43 used an economic model in the evaluation of bDMARDs, including anti-TNFs, for adult RA. Table 2 summarises if, and how, ADEs were considered in the 43 economic models reviewed. Table 3 reports the rationales for the degree of inclusion of ADEs stated in the associated studies. Nine studies [46] [47] [48] [49] [50] [51] [52] [53] [54] were critically appraised because they had considered the direct implications of ADEs on healthcare costs and/or patient HRQoL in the economic model.
Economic Models for Anti-TNFs for RA with No
Consideration of the Costs or Consequences of ADEs
Of the 34 studies that did not consider the wider implications of ADEs in the economic models, 16 did not incorporate ADEs in any form [26, 38, 41, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] . Only four acknowledged the omission [38, 41, 56, 67] . ADEs were implicitly included within an all-cause treatment-discontinuation parameter in 15 studies [39, 40, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] , and three studies [32, 36, 37] explicitly modelled the early cessation of treatment due to ADEs. The most commonly cited reasons for not comprehensively including the implications of ADEs were a relative paucity of data and a negligible impact on the relative costs and consequences of treatment. An overview of these 34 studies can be found in the online supplementary content (see Online Resource 2). As Fig. 2 indicates, there was no apparent time trend to the inclusion of the direct implications of ADEs from antiTNFs or bDMARDs into the economic models reviewed. The NICE TAG reports TA130 and TA195 2 summarised a total of eight manufacturers' models, and scrutiny of these revealed five instances where ADEs had potentially been included. Table 4 contains an overview of the identified assumptions made about ADEs in the eight manufacturers' models. One manufacturer's model (Bristol Meyers-Squib: TA195 [32] ) apparently incorporated a direct disutility resulting from ADEs, but, in general, there was insufficient detail about the model's assumptions to assess the bias or credibility of the reports. Considering the potential scope for bias from subjective reporting due to a personal interest in the final report's conclusions, it was not considered appropriate to include the summaries of the manufacturers' economic models in the critical review.
The most recent version of the BRAM used by the TAG (TA195) had not accounted for the direct costs or consequences of ADEs from anti-TNFs and was therefore excluded from the critical review. A discrete annual cost for ''adverse events'' for each bDMARD was included in a sensitivity analysis, but the types of adverse events considered were not reported. The inclusion of the cost estimates did not affect the base-case results. Table 5 summarises the key characteristics of the nine models that included the direct costs and/or consequences of an ADE. An overview of the assumptions identified regarding ADEs in these nine modelling studies is presented in Table 6 .
Critical Review
Terminology and Type of ADEs
Inconsistent terminology was used both within and across the nine studies to refer to ADEs. 'Adverse events,' 'adverse effects,' 'toxicity,' 'side effects,' 'serious infections,' and 'adverse drug effects' (ADEs) appeared to be used interchangeably. Ascertaining whether, and precisely which, ADEs had been included in the models was therefore difficult.
Seven of the nine studies [46, 47, [49] [50] [51] [52] [53] focussed on the costs and consequences of serious ADEs only. Subjectively less serious ADEs such as injection site reactions were included as clinical events in four of the nine models [48] [49] [50] 54] , two of which [48, 54] also incorporated a cost impact. The remaining five models [46, 47, [51] [52] [53] did not account for less serious ADEs, which were typically assumed to elicit a negligible impact on healthcare costs or patient HRQoL.
Two studies by Choi et al. [49, 50] explicitly included ADEs in the model structure as minor or major events caused by ''a toxic reaction to a drug''. These studies defined major drug toxicity as any ADE that required hospitalisation or the extended use of outpatient facilities. Minor toxicity was defined as any ADE requiring the minimal use of outpatient services alone. Spalding and Hay [47] also modelled drug toxicity but limited it to the serious infections tuberculosis (TB), septicaemia, and pneumonia. Nguyen et al. [51] and Kobelt et al. [52] incorporated serious infections in the analysis, which were assumed to be an adequate proxy for all anti-TNF-related ADEs. Neither study detailed which types of serious infections were included.
Chiou et al. [48] defined ADEs as ''adverse events from treatment''. The types of ADEs encompassed in each severity category (mild, moderate, or severe) were not exhaustively detailed, but examples were provided to illustrate how the different ADEs were distinguished. Injection-site reactions, dizziness, and abdominal pain were considered mild ADEs. Sinusitis and upper respiratory infections were classed as moderate ADEs, whereas sepsis and TB were deemed severe ADEs.
Bansback et al. [54] , Lekander et al. [46] , and Davies et al. [53] referred to the occurrence of ''adverse events,'' implying the lack of an assumed causal relationship between the events and the respective drugs. However, in Bansback et al. [54] , the possible occurrence of an adverse event (mild, moderate, or severe) was directly associated with a bDMARD. In Lekander et al. [46] , two types of serious infection were considered: TB and a generic serious infection assumed to encompass all other types. Conversely, a clear causal link between the drugs and the occurrence of adverse events was not established by Davies et al. [53] . Table 5 Summary of studies (n = 9) that explicitly included the costs and/or consequences of ADEs in the economic model 
Incorporating Risk of ADEs: Characteristics of the Economic Models
There was substantial variation amongst the nine studies in terms of the methods used to incorporate ADEs into the economic models and the associated assumptions made. Differences arose in (i) the specific type of model used, which then influenced how ADEs were parameterised; (ii) the time interval during which ADEs could occur; (iii) the assumptions made regarding the impact of an ADE on the disease and treatment course; and (iv) the extent to which the risk of an ADE was adjusted for distinct patient sub-populations. The nine identified studies encompassed six cohort-level models (three decision trees [48] [49] [50] ; three Markov-type models [46, 47, 51] ) and three individual patient-level models (one discrete event simulation [52] ; two individual sampling models [53, 54] ) [81] . Parameterisation of the risk of ADEs included probabilities, rates, and likelihoods relating to discrete and joint health states, pathways and events. The studies could be dichotomised in terms of the risk interval assumed for the occurrence of ADEs: four studies [46, [48] [49] [50] assumed a short-term risk only (relative to the time horizon of the model or average treatment duration) while five [47, [51] [52] [53] [54] assumed, either implicitly or explicitly, that the risk persisted over time. This heterogeneity suggests a lack of consensus over how best to include ADEs and their possible effects in economic models for RA.
Chiou et al. [48] directly included ADEs within the structure of a decision tree, structured to represent two 6-month periods in which incidents of ADEs occurred (at 6 and 12 months). The health states modelled were contingent on both treatment response and ADEs (no ADE, mild, moderate, severe). Choi et al. [49, 50] also used a decision tree in which drug toxicity, the probability of which was limited to the first 8 weeks of treatment, was incorporated as a discrete branch emanating from the first chance node [29] . Subsequent branches then determined the probability of toxicity being major or minor.
Individual sampling models were used by Bansback et al. [54] and Davies et al. [53] . Kobelt et al. [52] used a discrete event simulation model. Bansback et al. [54] incorporated ADEs (mild, moderate, or serious), stratified by treatment type and held constant over time, as possible events in each 6-month interval. Spalding and Hay [47] incorporated rates of drug discontinuation due to ADEs in each time period into a backward induction Markov-chain model via the probabilities of transitioning between the possible health states. Davies et al. [53] also included adverse events through a treatment-specific probability of withdrawal per 6-month cycle (Table 1) . Kobelt et al. [52] factored instances of ADEs into an overall treatment withdrawal parameter modelled as the time to all-cause treatment discontinuation.
Cohort-based Markov models were used by Nguyen et al. [51] and Lekander et al. [46] . The former included a constant rate of withdrawal due to serious infections in each model cycle. The latter modelled the combined risk of experiencing TB or one other generic treatment-related serious infection during the first model cycle only. Lekander et al. [46] referred to evidence of a decreasing risk of serious infections in the duration of treatment as justification for limiting the risk period to the first year of active therapy. It was however acknowledged that TB could occur at any point throughout treatment and restricting the risk to the first model cycle was a generalisation made to facilitate and simplify the modelling process.
Incorporating Costs and Consequences
All nine studies included some estimation of the direct healthcare costs of treating ADEs, but this was reported with differing degrees of detail. In contrast, only two studies [46, 48] included some consideration of the consequences. Only one study [46] included an estimate of the direct and independent impact of an ADE on patient HRQoL. Overall, there was inconsistency between the studies in how they approached ADEs from the different drug therapies evaluated. For example, monitoring costs associated with ADEs from nbDMARDs were more comprehensively quantified than the costs of anti-TNF-related ADEs.
Choi et al. [49, 50] assumed that bDMARDs posed no threat of ADEs (Tables 5, 6 ). bDMARDs were therefore associated with zero additional costs despite an additional toxicity cost being incurred by the other non-biological drug options. Davies et al. [53] applied an independent fixed cost for adverse events in each model cycle, but did not link the cost to the duration of treatment or any specific adverse event. The cost for all anti-TNFs evaluated, and nbDMARDs, was assumed equal.
Chiou et al. [48] differentiated resource use by ADE severity. Mild drug complications were ascribed two physician visits per year, blood counts and liver function tests with chest-X-rays. An additional 10 days of antibiotics and a urine analysis were included for moderate complications. For severe complications, resource use was based on the combined average length of stay in hospital for pneumonia and sepsis. Lekander et al. [46] and Spalding and Hay [47] took an approach that was similar to, but less detailed than, the approach of Chiou et al. [48] . Lekander et al. [46] attributed 6 days in hospital for TB and 10 days for the generic class of serious infections modelled. Spalding and Hay [47] calculated treatment-specific average ADE costs. The combined incident rates for the serious infections TB, sepsis and pneumonia were multiplied by the associated mean cost for inpatient treatment.
Bansback et al. [54] , Nguyen et al. [51] , and Kobelt et al. [52] also based the direct costs of ADEs on the use of healthcare resources arising from hospitalisations. Bansback et al. [54] based resource use on average monitoring and treatment requirements, which included outpatient visits, liver function tests, and infusions. Two separate estimates were applied: the first in the initial 6-month interval and the second in all proceeding periods. It was not clear whether the monitoring and treatment schedules reported were specific to ADEs or were more generalised estimates. Nguyen et al. [51] assumed an inpatient stay of 6 days for all serious infections and included one course of antibacterial therapy. Kobelt et al. [52] applied a fixed cost per hospitalisation but did not detail which specific resources were included in the value.
ADEs were predominantly assumed to preclude treatment continuation in the majority of studies rather than directly affect patient HRQoL or treatment effectiveness. Of the seven studies undertaking cost-utility analysis [46] [47] [48] [51] [52] [53] [54] , only Lekander et al. [46] estimated the direct effect of ADEs on patient HRQoL. Davies et al. [53] , Bansback et al. [54] , Kobelt et al. [52] , Nguyen et al. [51] , and Spalding and Hay [47] only evaluated the indirect consequences associated with discontinuing treatment. Chiou et al. [48] partially adjusted patient HRQoL for ADEs as utility values associated with the respective health states were mutually contingent on treatment response and the degree of ADE experienced.
Choi et al. [49, 50] assumed equivalence in the clinical impact of mild and no toxicity. Major toxicity affected clinical outcomes by requiring the immediate cessation of treatment. Adverse events did not elicit any direct clinical impact in the economic model presented by Davies et al. [53] unless their occurrence precluded subsequent bDMARD treatment. This was only relevant in one treatment sequence wherein two successive bDMARDs were considered (see Table 5 ). In all other sequences, the incidence of adverse events was assumed included in the drug-specific response rates. A similar approach was taken by Spalding and Hay [47] , Nguyen et al. [51] , and Kobelt et al. [52] . The possible clinical impacts of ADEs were assumed captured in the state-transition probabilities for the cohort-based models [47, 51] and in the time to treatment discontinuation for the patient-level model [52] . Bansback et al. [54] assumed patients stopped treatment if a severe ADE occurred. Where patients had initially experienced a positive response to treatment, the occurrence of a mild or moderate ADE did not unequivocally result in the discontinuation of treatment.
Chiou et al. [48] only partially accounted for utility decrements. The impact of an ADE per se on patient HRQoL was not incorporated, as preference weights were ascribed to specific health states that reflected both the response to treatment and degree of ADE experienced. Lekander et al. [46] explicitly estimated the direct impact of ADEs on patient utility. It was assumed that, whilst a patient was in hospital receiving treatment for an ADE, their utility rebounded to the pre-treatment level. This corresponded to an average utility decrement of 0.11. ADEs also resulted in patients discontinuing the current treatment thereby incurring the additional indirect costs and consequences arising from the deterioration of the disease.
Data Sources
Data informing the incidence, cost, and consequences of ADEs were drawn from a myriad of sources (Table 5) . Incidence-related data were predominately abstracted from secondary sources including clinical trial reports, published observational studies, and, in three instances, drug package inserts [48, 50, 54] . Cost and resource use data were mainly taken from published studies and national pricing schedules. Utility data were derived directly from patients in one study [48] through a preference elicitation exercise undertaken as part of a sister study, and based on analyst assumptions in the other [46] .
Choi et al. [49, 50] used published literature and reports from individual clinical trials to inform toxicity-based parameters. Rates of ADEs were taken from a review of clinical trial publications by Chiou et al. [48] and Nguyen et al. [51] . Spalding and Hay [47] extracted incidence data from selected clinical trial reports, and Davies et al. [53] and Bansback et al. [54] both estimated treatment withdrawal rates due to ADEs from the same Swedish observational study [82] . Swedish real-world clinical data were also used by Lekander et al. [46] and Kobelt et al. [52] , wherein rates of ADEs were taken from registry studies.
The reviewed studies varied in their preferred sources for ADE-related resource use and direct healthcare costs. Bansback et al. [54] utilised expert opinion. Spalding and Hay [47] estimated direct costs using data from the same clinical trials as the rates of ADEs were taken. Kobelt et al. [52] derived fixed estimates of hospitalisation and direct treatment costs from a survey of RA patients. Lekander et al. [46] based costs on official reference-cost schedules, as did Chiou et al. [48] . Patient-level data reported in a national health database were used by Nguyen et al. [51] , and Choi et al. [49, 50] used reports of hospital charges for the treatment options assumed to incur toxicity costs (methotrexate and sulfasalazine options only) in both studies. Davies et al. [53] estimated adverse event costs from expert opinion, physician fee schedules, and official reference-cost schedules.
Quantifying Uncertainty and Sensitivity Analysis
Seven [46] [47] [48] [49] [50] [51] 54] of the nine studies included ADE parameters in a univariate sensitivity analysis. The sensitivity analyses undertaken included utilising different data sources and varying the parameter values within a predefined range (see Table 6 ).
Bansback et al. [54] altered the source of adverse event data. Rates of adverse events were firstly assumed equal for all treatment groups to determine the impact of an optimistic estimate of occurrence. Secondly, to reflect a more cautious estimation, adverse event rates were set equal to those reported in the respective drug package inserts. The impact on the incremental cost-effectiveness ratio (ICER) reported was minimal.
In the two studies by Choi et al. [49, 50] , the probability of drug toxicity, the proportion experiencing major toxicity, and the associated monitoring costs were varied between 50, 80 and 100 % of the baseline values for selected drugs only. The probability of bDMARD toxicity occurring was not altered from the baseline value of zero. Results were robust to the changes in the ADE parameters evaluated. A thorough examination of the potential impact of uncertainty in the ADE parameters was presented by Chiou et al. [48] and Lekander et al. [46] . Both studies included all ADE cost and probability variables in univariate sensitivity analyses. Chiou et al. [48] varied costs within a 50-200 % range of the baseline values, while the baseline probabilities were increased and decreased by 50 %. Neither the costs nor probabilities of ADEs were reported to affect the baseline ICER. Lekander et al. [46] also found the initial cost-effectiveness results to be relatively unaffected by implementing a discrete utility decrement (equal to 0.2) upon the occurrence of an ADE, or by the complete exclusion of ADEs.
Nguyen et al. [51] altered the probability of serious infections between zero and 0.15 for all the drugs compared. The resulting ICERs were minimally affected. In the sensitivity analyses undertaken by Spalding and Hay [47] , the cost ascribed to ADEs was set equal for all the drugs compared. As in the studies of Chiou et al. [48] , Choi et al. [49, 50] , Bansback et al. [54] , Lekander et al. [46] , and Nguyen et al. [51] the initial study results were robust to changes in the ADE parameters. Kobelt et al. [52] and Davies et al. [53] did not appear to include any ADE parameters in the sensitivity analyses conducted.
Discussion
This systematic review aimed to establish if, and how, the direct costs and consequences associated with ADEs have been considered in model-based economic evaluations of anti-TNFs for adults with RA. Relevant models were appraised with the objective of improving future economic models. The findings of this review have shown that existing economic models have not systematically incorporated all clinical and economic outcomes relevant to the decision problem. The findings contradict recommendations in current national UK guidelines [83] and also in the reference case for economic evaluations of drug treatments for RA proposed by the Outcome Measures in Rheumatology Task Force (OMERACT) [84] , which explicitly state the need to consider the impact of 'adverse effects,' 'adverse events,' and 'toxicity'.
Only around one-fifth of the model-based economic evaluations reviewed had explicitly accounted for the costs or HRQoL implications of ADEs in the respective models. Perhaps surprisingly, the tendency to omit ADE-related parameters from models remained relatively consistent over time. Given that the safety data available to studies published to coincide with the emergence of the first antiTNFs were predominately limited to those from clinical trials, the omission of ADEs may be more understandable.
Results from short-run clinical trials and related metaanalyses have been conflicted as to the degree of risk posed by anti-TNFs relative to nbDMARDs [11, 12, 14, 15] . Yet, studies published more recently were just as likely to have excluded ADEs from the economic model. This observation is at odds with the prediction that, as the availability of data from appropriate sources on the risks and wider implications of ADEs from anti-TNFs has increased, the number of model-based economic evaluations considering ADEs and the resulting costs and consequences would also have increased. In addition, this observation does not accord with the recognised need to update model parameters as new evidence becomes available [33, 83, 85] . The evidence base on the safety of anti-TNFs has significantly improved with the establishment and maturation of national biologics registers in, for example, the UK [86] , Italy [87] , Germany [88] , the Netherlands [15, 89] , and Sweden [90] . Results from long-term observational studies show an elevated risk of ADEs from anti-TNFs when used in a clinical real-world setting [15] . However, the omission of ADEs from recent economic models does raise the question of whether expensive national registry studies are themselves cost effective if the data generated are not subsequently used in economic analyses informing national healthcare decision making.
The review of the economic models submitted as part of the NICE TA process also identified a general omission of the wider implications of ADEs. Although this may be a reflection on resource (time and financial) constraints imposed by the NICE TA process and on the availability of appropriate data, the implications for the evidence base presented to UK decision makers do need to be considered. In addition, this review found the assumptions and methodologies employed in the BRAM were frequently adopted in the other economic models reviewed, perhaps suggesting that the NICE TA is widely believed to exemplify 'best practice' in relation to model-based economic evaluations. It follows that the omission of the costs and consequences of ADEs from the BRAM could further affect the evidence base provided to decision makers by influencing the design of novel economic models for the evaluation of bDMARDs for adults with RA. This finding highlights the need for decision analysts to continually reassess the relevance of a model structure to the decision problem and use an iterative model conceptualisation process complete with continued consultation with experts in the field [91, 92] throughout the parameterisation and execution of the final model in order to develop a reliable and robust decision analytic model that best reflects the current decision problem [30, 93, 94] .
This review also indicated that the specific type of model used in the economic evaluation may have influenced the extent to which, and how, ADEs were incorporated. Decision trees are best suited to decision problems with short-time horizons [81] , which is not consistent with a chronic and remitting disease like RA. Markov-type models, adopted in three studies [46, 47, 51] , may prove more amenable to incorporating ADEs from anti-TNFs over the longer term, but their suitability is still affected by a number of factors. Chiefly, Markov models analyse the relative costs and benefits for a patient cohort at the aggregate level and are therefore limited in their ability to capture heterogeneity in patient characteristics [30, 95] . As certain characteristics such as increasing age, gender, and the presence of comorbidities may influence a patient's risk of ADEs [18, 87, 96] , it follows that Markov models may not suitably capture the respective treatments' risk profiles. In addition, Markov models are further restricted by the Markovian memory-less property whereby transition probabilities between health states are conditionally independent of past events, including the time in any given health state [29, 81] . Although relaxable [97] , the strict application of the Markovian property means a Markov model may not adequately reflect current evidence that suggests treatment history affects the risk of ADEs [98] and the occurrence of one ADE is likely to increase the risk of subsequent ADEs.
Patient-level individual sampling models and discrete event simulations could provide greater flexibility in how ADEs are incorporated in economic models by including patient histories and differential risks conditional on specific characteristics [99] . Individual sampling models and discrete event simulations therefore potentially allow for a more detailed depiction of each treatment's risk profile by using time-to-event data. However, this potential advantage was not fully exploited by the patient-level models identified in this review in regard to ADEs.
Considering the variety of model types available to a decision analyst, it is important that the type of model chosen is appropriate for the decision problem in question [81] . Furthermore, when developing the model structure, the decision analyst, faced with the unavoidable trade-off between the degree of real-world representativeness and the complexity of a model [100] , must clearly report and justify all decisions and assumptions made throughout the modelling process unambiguously and transparently.
Once the model type has been chosen, the next, and perhaps the biggest, challenge for incorporating ADEs is the availability of appropriate and high-quality data. This review suggests that a pragmatic approach was often taken in existing models: rates of ADEs were taken from clinical trial reports despite evidence to suggest that rates observed in clinical trials are generally lower than those seen when the drug is used in clinical practice [69, 101] . The potential limitations of randomised controlled trials in terms of being able to provide useful data on ADEs [12, 102] suggests a need to move beyond trial data as the gold standard and consider generating quality real-world comparative effectiveness data from patient registries. Registry data are not without limitations, most notably the risk of selection/ channelling bias [103] and confounding through indication, but statistical adjustments can be made to account for potential biases. In this way, the generalisability of realworld data might make registry data preferable over clinical trial data for the parameterisation of model-based economic evaluations. Greater acknowledgment in methods guidelines of both the limitations of clinical trials and the advantages of observational studies to supply meaningful safety data [18] may give analysts greater confidence to deviate from the 'gold standard' and apply appropriate ADE data derived from real-world clinical settings.
While the apparent lack of data on ADEs may be driven by a tendency in clinical trials to focus on reporting positive outcomes, it may also be partly due to the drug development, regulatory, and reimbursement processes and the general lack of attention to equivalently detailed reporting of harms and benefits. There have also been concerns raised over transparency in how treatment risks and benefits are assessed by regulatory bodies and at the reimbursement decision level [104] .
In practice, the comprehensiveness of the cost and resource use data utilised in economic models is constrained by the cost of obtaining more accurate data. This, often implicit, trade-off can result in data collection being focused on key cost drivers identified ex ante. Indeed the majority of the reviewed studies [47, 48, 51, 52, 73] restricted ADE costs to hospitalisations for serious infections. While ADE-related healthcare costs are driven by inpatient care for serious infections [2, 61, 66, 105] , the risk and implications of biasing the cost estimates entering the cost-effectiveness equation by over generalising the burden of ADEs from anti-TNFs on healthcare resources do need to be considered and, again, adequately justified by the decision analyst. This review found that there was asymmetry in how the costs and consequences of ADEs from anti-TNFs were compared with nbDMARDs [47, [49] [50] [51] [52] [53] [54] . There was a lack of consistency in terms of which items of resource use were included in the relevant comparators [29] , which resulted in different components entering the denominator of the respective treatments' cost-effectiveness equation. The effect of this is to systematically favour the less comprehensively costed drug treatment. A cost impact for ADEs was incorporated in seven of the nine critically reviewed studies [47, [49] [50] [51] [52] [53] [54] without suitably adjusting for the potential impact on patient utility. This imbalance in terms of the inclusion of costs and consequences may be driven by the existence of a more clearly tangible relationship between ADEs and the use of healthcare resources than between ADEs and patient HRQoL. But given that bDMARDs, and specifically anti-TNFs [18, 106, 107] , increase the risk of ADEs such as serious infections relative to nbDMARDs, by not suitably adjusting patient HRQoL the absolute and relative benefits of bDMARDs will likely be overestimated. In addition, ADEs, and the implications for HRQoL, will determine whether a patient continues with treatment [31] and could affect the overall acceptability of the treatment to the target population. Assuming that ADEs do not directly affect patient HRQoL is therefore improbable.
One of the key arguments for using model-based economic evaluations is the ability to explore, quantify, and provide decision makers with an explicit and transparent account of how different sources of uncertainty affect the study's final results [108] . For example, scenario and sensitivity analyses can be used to assess the risk of biasing results from utilising certain data [29] . Exploring the impact of utilising different data sources on the baseline results is especially important when there is conflicting evidence. There is less definitive evidence on the magnitude of the risk differential between more recently licensed bDMARDs (see for example [11, 16, 18] ). Hence, novel studies comparing bDMARD strategies should ideally determine the potential of biasing results against individual strategies through the subjective selection of data. Formally quantifying how robust the baseline results are to changes in particular parameters can also be useful in identifying and informing decision makers of areas where further research is needed [109] . Where gaps in the evidence base are identified during the modelling process, analysts can quantify the likely cost of garnering additional information through expected value of perfect information analyses [109] .
However, less than a quarter of the total 43 models identified included ADE-related parameters in their sensitivity analyses. Furthermore, two of the critically reviewed studies [49, 50] conducted univariate sensitivity analyses on ADE parameters for only a sub-set of the drugs evaluated. Although the cost-effectiveness results reported in the seven studies conducting univariate sensitivity analyses were robust to changes to ADE parameters, it would not be correct to conclude that subsequent economic evaluations of anti-TNFs, or bDMARDs, need not include ADEs. As a clinically important outcome of treatment [12] , ADEs affect both the individual patients receiving the drugs and those forced to bear the resulting healthcare costs. As a result they are important to decision makers [110] and should therefore be directly and transparently incorporated into economic models. While recent efforts have been made by OMERACT to standardise the practice of economic modelling of drug treatments for RA [84] , the lack of concordance overall regarding the assumptions and characteristics of the economic models highlighted in this review makes clear that further effort is required. Explicit reference to ADEs in methods guidelines and reference cases could encourage novel economic models for antiTNFs and bDMARDs, to better consider the implications of ADEs. The apparent lack of consideration of the impact of ADEs is not isolated to model-based economic evaluations of anti-TNFs for RA and has, however, been recognised as a more general challenge of economic evaluations of health technologies. Craig et al. [21] addressed the inclusion of adverse events in health technology assessment reports published as part of the NICE TA process and noted that current guidelines for economic models do not provide satisfactory instruction on the treatment of ADEs and further research is needed to address this gap.
Some key limitations of this systematic review are related to the study inclusion criteria and the need to rely on what was reported rather than what a decision analyst may have done as part of the modelling process. Only model-based economic evaluations were included and prospective trial-based evaluations were excluded. This focus was used because model-based designs for conducting cost-effectiveness analysis are currently used in UK-based decision-making processes by NICE. In addition, trial-based evaluations are unlikely to be able to provide long-term estimates of the implications of ADEs for the cost-effectiveness of anti-TNFs. Furthermore, it was necessary to rely on what the study explicitly stated and reported. Relying on what a paper reports is a limitation because journal requirements and word count constraints could have restricted the ability of authors to fully report the complete set of assumptions and data sources used, and specific to this review, the incorrect use of risk-related terminology in the identified studies could have resulted in studies being misclassified and excluded. However, since over three-quarters of the reviewed studies did not report incorporating the costs or consequences of ADEs such exclusions are either unlikely to have occurred or to have significantly changed the conclusions drawn from this systematic review.
Conclusions
Healthcare decision makers must be provided with the best evidence available if they are to be confident of making informed and defensible decisions. Ideally, the evidence base should include all important treatment outcomes. This systematic review identified that model-based economic evaluations of anti-TNFs for adult RA have not routinely or comprehensively included, or in some instances adequately described, the costs or consequences of ADEs.
Several important barriers to a more comprehensive and methodologically consistent approach to the inclusion of the risks from drug treatments in model-based economic evaluations do remain: (i) confusion regarding the weight decision makers ascribe to the dis-benefits from drug treatments; (ii) insufficient ADE-specific guidance provided in best practice guidelines for economic models; and (iii) a lack of available model-appropriate ADE data. To advance current practice in economic evaluations and improve the quality of model-based data presented to healthcare decision makers therefore requires several actions: (i) greater efforts need to be made to generate and utilise high-quality long-term safety data on the use of antiTNFs in adult RA; (ii) empirical research needs to be undertaken to identify and quantify the impact of, and possible methods for, including ADEs in economic models to inform future good practice guidelines for economic modelling; and (iii) current modelling guidelines and reference cases need to be updated to explicitly identify ADEs as an important treatment outcome and address how they might be directly incorporated into decision analytic models.
The more complete inclusion of the possible costs and consequences of ADEs will provide decision makers with more robust, acceptable, and reliable estimates of the relative cost-effectiveness of anti-TNFs for adult patients with RA. In doing so, patient access to effective treatments and the efficient use of scarce healthcare resources will be continued.
